The SBS20 mutational signature is etiologically associated with concurrent POLD1 exonuclease mutation and defective MMR deficiency (Figure 3E) and was previously identified in endometrial cancer with this co-deficiency [31,32]. Here, POLD1 is linked to endometrial cancer.